The Renaissance of Cyclin Dependent Kinase Inhibitors
Tobias Ettl1, Daniela Schulz1,2, Richard Josef Bauer1,2
1Department of Oral and Maxillofacial Surgery, University Hospital Regensburg, 93053 Regensburg, Germany.
Abstract:
Cyclin-dependent kinases (CDK) regulate cell cycle progression. During tumor development, altered expression and availability of CDKs strongly contribute to impaired cell proliferation, a hallmark of cancer. In recent years, targeted inhibition of CDKs has shown considerable therapeutic benefit in a variety of tumor entities. Their success is reflected in clinical approvals of specific CDK4/6 inhibitors for breast cancer. This review provides a detailed insight into the molecular mechanisms of CDKs as well as a general overview of CDK inhibition. It also summarizes the latest research approaches and current advances in the treatment of head and neck cancer with CDK inhibitors. Instead of monotherapies, combination therapies with CDK inhibitors may especially provide promising results in tumor therapy. Indeed, recent studies have shown a synergistic effect of CDK inhibition together with chemo- and radio- and immunotherapy in cancer treatment to overcome tumor evasion, which may lead to a renaissance of CDK inhibitors.
Insights
Cyclin-dependent kinases (CDKs) are key regulators of cell division. Inhibiting CDKs shows promise for treating cancers, especially in combination therapies for head and neck cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Cyclin-dependent kinases (CDKs) are crucial regulators of the cell cycle.
- Dysregulation of CDKs contributes to uncontrolled cell proliferation in cancer.
- Targeted CDK inhibition has emerged as a successful cancer treatment strategy, with CDK4/6 inhibitors approved for breast cancer.
Purpose of the Study:
- To provide insights into the molecular mechanisms of CDKs.
- To offer an overview of CDK inhibition strategies.
- To summarize recent advances in treating head and neck cancer using CDK inhibitors.
Main Methods:
- Review of molecular mechanisms of CDK regulation.
- Analysis of clinical data on CDK inhibitors in various cancers.
- Synthesis of current research on CDK inhibitor combinations.
Main Results:
- CDK inhibitors demonstrate therapeutic benefits across diverse tumor types.
- Combination therapies involving CDK inhibitors show synergistic effects.
- CDK inhibition combined with chemo-, radio-, and immunotherapy can overcome tumor evasion.
Conclusions:
- CDK inhibitors represent a significant advancement in cancer therapy.
- Combination strategies with CDK inhibitors hold substantial promise for improving treatment outcomes.
- CDK inhibitors may experience a resurgence in cancer treatment due to their efficacy in overcoming resistance mechanisms.
Related Concept Videos
02:34Inhibition of Cdk Activity
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:39Positive Regulator Molecules
00:50Anaphase Promoting Complex
01:22PI3K/mTOR/AKT Signaling Pathway
01:23Negative Regulator Molecules